NIH And 10 Biopharmas Hatch Plan To Accelerate And Improve Therapeutic Pathway Research
This article was originally published in Pharmaceutical Approvals Monthly
With $230 million from industry and NIH, the Accelerating Medicines Partnership seeks to hasten and improve the success rate for discovery of biomarkers and therapeutic pathways in Alzheimer’s, type 2 diabetes, rheumatoid arthritis and lupus.
You may also be interested in...
NIH Director Francis Collins describes evolution of existing collaborations and how the two agencies might facilitate development of gene therapy, such as by having a common template for regulatory review.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.
During a three-day visit in Shanghai, PhRMA Chairman Robert Hugin met local stakeholders and outlined the organization’s advocacy priorities in China amidst the evolving Drug Administration Law.